603658 安图生物
2024/03 - 三个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入1,089,1955.09%4,443,6564,441,6273,765,9172,978,132
减:营业总成本777,943-0.98%3,214,9603,278,3892,832,0952,193,102
    其中:营业成本386,453-4.26%1,552,2451,783,6571,525,6281,198,723
               财务费用2,054144.64%8,788(2,041)14,58920,863
               资产减值损失1,374-105.04%(32,692)(35,777)(619)(1,664)
公允价值变动收益3,407--580--3394
投资收益22,968-38.03%129,381118,585108,34649,888
    其中:对联营企业和合营企业的投资收益(1,257)1,425.91%(3,369)2,000764,704
营业利润363,98434.36%1,365,7481,296,3821,076,152856,366
利润总额361,81232.90%1,362,5441,293,7151,065,549844,533
减:所得税费用33,11332.07%138,413105,03385,69387,442
净利润328,69932.98%1,224,1311,188,682979,856757,091
减:非控股权益4,487-12.06%6,69221,2456,1939,297
股东净利润324,21233.93%1,217,4391,167,437973,663747,794

市场价值指针
每股收益 (元) *0.56033.33%2.1002.0001.6601.340
每股派息 (元) *----1.0520.8000.7200.850
每股净资产 (元) *14.9769.41%14.55913.27512.41214.363
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容